December 17, 2013, Redwood City, Ca., USA – Versartis, Inc., a biopharmaceutical company, announced the appointment of Joshua T. Brumm as its first chief financial officer. <br /><br />Mr. Brumm was most recently Executive Vice President of Finance at Pharmacyclics Inc. where he was the Principal Financial Officer and Principal Accounting Officer with responsibilities for Corporate Finance, IT, Facilities and Procurement.<br /><br />Previously, as Chief Financial Officer and Senior Vice President for ZELTIQ Aesthetics, Inc. he led the company’s 2011 initial public offering and also served in senior leadership roles in International Sales, Corporate Development and Investor Relations.<br /><br />Prior to joining ZELTIQ, Mr. Brumm served as Director of Finance at Proteolix, Inc., a private biotechnology company acquired by Onyx Pharmaceuticals. Earlier in his career, Mr. Brumm held the positions of Investment Banking Associate as a member of the West Coast Healthcare Team at Citigroup Global Markets, Inc. and as an Investment Banking Analyst for the West Coast Healthcare Team at Morgan Stanley.<br /><br />Mr. Brumm holds a BA in Business Administration from the University of Notre Dame. 